Figure 4.

PsL-EGFmAb inhibits human DC maturation in vitro. Human CD14⁺ monocytes from healthy donors were isolated using the MACS method and cultured in RPMI 1640 complete medium in the presence of 50 ng/ml human GM-CSF and 20 ng/ml human IL-4 for five days to produce imDCs. mDCs were induced by further treatment with 50 ng/ml TNF-α. In PsL-EGFmAb group, 10 μg/ml PsL-EGFmAb was also added before TNF-α treatment. Expression of HLA-DR, CD80, CD83 and CD86 on imDCs, mDCs, or PsL-EGFmAb-treated DCs was detected by flow cytometry. A, imDCs. B, mDCs. C, PsL-EGFmAb-treated DCs (black line). Appropriate isotype antibodies were used as controls (gray line). Data were representative of at least three independent experiments.